GenScript ProBio, a global Contract Development and Manufacturing Organization (CDMO), announced a memorandum of understanding (MOU) with South Korea’s ACT Therapeutics to collaborate on cell therapy development. GenScript will act as ACT’s global partner, providing plasmid and virus vector services to advance ACT’s chimeric antigen receptor (CAR) T cell therapy pipeline. Financial terms were not disclosed.
Partnership Details
The partnership focuses on supporting ACT’s CAR-T candidates targeting solid tumors. ACT’s pipeline aims to overcome tumor microenvironment immune suppression and activate surrounding immune cells. GenScript ProBio will leverage its expertise in plasmid and viral vector development to aid ACT’s clinical programs.
Company Backgrounds
- ACT Therapeutics: Founded in 2020, the firm specializes in next-generation CAR-T therapies for solid tumors.
- GenScript ProBio: A subsidiary of China’s GenScript Biotech, with operations in the US, Netherlands, South Korea, Shanghai, Hong Kong, and Nanjing.-Fineline Info & Tech
